Table 1.
Genital tubercle (GT) defects of Pdgfra-cKO embryos of different Tm groups
| Tm | Collection | Embryos (n) | Pdgfra-cKO (n) | GT defects (n) |
|---|---|---|---|---|
| E9.5/10.5 | E14.5 | 146 (M:64; F:82) | 37 (25%) (M:17; F:20) | +(37) |
| E18.5 | 143 (M:78; F:65) | 39 (27%) (M:12; F:27) | +(39) | |
| E10.5/11.5 | E14.5 | 18 (M:8; F:10) | 5 (27%) (M:2; F:3) | +(1); ±(4) |
| E17.5 | 24 (M:13; F:11) | 7 (29%) (M:3; F:4) | ±(7) | |
| E11.5/12/5 | E17.5 | 8 (M:3; F:5) | 3 (37%) (M:1; F:2) | −(4) |
| E12.5/13.5 | E17.5 | 8 (M:4; F:4) | 3 (37%) (M:1; F:2) | −(4) |
Time of collection, number of total embryos and mutant embryos, genders, % of Pdgfra-cKO embryos, GT defects and number of mutants (in parenthesis) showing different GT defects of different Tm treatment groups were indicated. “+”: severe GT defects include the urorectal septum retardation, urogenital fold dysplasia, no ventral midline fusion of prepuce and untubularized urethra. “±”: mild GT defect includes slightly enlarged urethral opening, incomplete ventral midline fusion of prepuce, and proximal untubularized urethra. “−”: no GT defect
Tm tamoxifen, M male, F female